Melanoma – Cell and Gene Therapies 15-Market Assessment and Forecast to 2031
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Melanoma–Cell and Gene Therapies 15-Market Report Overview
The total market value for the 15M, which includes both CGTs and established/traditional melanoma therapies was $5.5 billion in 2021. The growing aging population, leading to an increased diagnosed incidence of melanoma across age groups will drive market growth during the forecast period.
Melanoma–Cell and Gene Therapies 15-Market Outlook, 2021-2031 ($ Billion)
Buy the Full Report to Know More About the Melanoma–Cell and Gene Therapies 15-Market Forecast
The melanoma–cell and gene therapies 15-market research report offers a comprehensive insight into the market through 2032. The report provides an overview of the disease including epidemiology, symptoms, diagnosis, disease management, countries where the disease is prevalent, and leading players associated with the market.
| Market Size (2021) | $5.5 Billion |
| Forecast Period | 2021-2031 |
| Key Regions | · APAC
· Europe · Middle East · North America |
| Leading Players | · Adaptimmune Therapeutics Plc
· Suzhou Bluehourse Therapeutics Co · Iovance Biotherapeutics Inc · Care Institute Netherlands; Miltenyi Biotec BV & Co KG · Bristol-Myers Squibb Co |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Melanoma–Cell and Gene Therapies 15-Market Dynamics
Potential requirement for administration at a specialized center, which may be a barrier to some markets or patients is hampering the market growth. However, the increased use of CGT agents alongside established therapies, particularly PD-1s could facilitate the movement of these agents into earlier lines of therapy or the adjuvant setting will people the market growth in the coming years.
Melanoma–Cell and Gene Therapies 15-Market Analysis by Treatment
- Melanoma patients have relatively effective first-line and second-line treatment options, which makes CGT therapies unlikely to penetrate first-line or second-line therapy.
- CGT has increased potential to address some unmet needs in the melanoma treatment landscape, specifically by providing therapeutic options for patients who have relapsed or are refractory to targeted therapy or immune checkpoint inhibitors.
Buy Full Report for More Insights into the Melanoma–Cell and Gene Therapies 15-Market Treatment
Melanoma–Cell and Gene Therapies 15-Market Segmentation by Regions
North America had the highest sales in 15MM in the melanoma-cell and gene therapies 15-market.
A few of the key regions in the market are APAC, Europe, Middle East, and North America.
Melanoma–Cell and Gene Therapies 15-Market Analysis by Regions, 2021 (%)
Buy Full Report for More Regional Insights into the Melanoma–Cell and Gene Therapies 15-Market
Melanoma–Cell and Gene Therapies 15-Market -Competitive Landscape
Iovance Biotherapeutics is the top sponsoring company with six ongoing trials, which include three trials where Iovance is a collaborator. Furthermore, Replimune, Wuhan Binhui Biopharmaceutical, and Amgen follow with four ongoing clinical trials.
A few of the major players in the melanoma–cell and gene therapies 15-market are:
- Adaptimmune Therapeutics Plc
- Suzhou Bluehourse Therapeutics Co
- Iovance Biotherapeutics Inc
- Care Institute Netherlands; Miltenyi Biotec BV & Co KG
- Bristol-Myers Squibb Co
Melanoma–Cell and Gene Therapies 15-Market Analysis by Companies
Buy the Full Report to Know More About Companies in the Melanoma–Cell and Gene Therapies 15-Market
Melanoma–Cell and Gene Therapies 15-Country Outlook (Value, $ Billion, 2021-2031)
- APAC
- Europe
- Middle East
- North America
Scope
Melanoma cell and gene therapy market research includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and pipeline therapies with established mechanisms of action and cell & gene therapies by class, including early to late clinical-stage pipeline products, with a launch date assessment by market for melanoma. In addition to PBF sales data for the 8MM, this report contains sales forecast extrapolations for an additional seven geographical markets (7M), totaling 15 markets (15M).
Key Highlights
- Report deliverables include a PowerPoint report and Excel-based forecast model.
- Forecast includes 8 countries.
- Forecast covers 2021-2031.
- Seven markets are extrapolated, obtaining a 15-market value for all melanoma therapeutics.
Reasons to Buy
- Obtain cell & gene therapy sales forecasts across multiple regions
- Gain insight into promising early-stage approaches
Our indication-specific forecast models answer questions such as:
- What is the target patient pool for cell & gene therapies in each cancer indication?
- Which patient groups are more likely to receive these therapies?
- What does the cell & gene therapy clinical-stage pipeline look like in each cancer indication
- What is the anticipated breakdown between autologous and allogeneic cell therapies?
- When will cell & gene therapies launch in each market?
- What is the total market value projected for the forecast end, in 2031?
Replimune
Wuhan Binhui Biopharmaceutical
Table of Contents
Frequently asked questions
-
What was the melanoma–cell and gene therapies 15-market size in 2021?
The total market value for the 15M, which includes both CGTs and established/traditional melanoma therapies was $5.5 billion in 2021.
-
Which region had the highest sales in the melanoma–cell and gene therapies 15-market?
North America held the highest sales in the melanoma– Cell and Gene Therapies 15-market across the 8MM in 2021.
-
Who are the leading players operating in the melanoma–cell and gene therapies 15-market?
A few of the major players in the melanoma–cell and gene therapies 15-market are Adaptimmune Therapeutics Plc, Suzhou Bluehourse Therapeutics Co, Iovance Biotherapeutics Inc, Care Institute Netherlands; Miltenyi Biotec BV & Co KG, and Bristol-Myers Squibb Co among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports



